Navigation Links
Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study

WILMINGTON, N.C., Jan. 19 /PRNewswire/ -- Intercell AG has retained Inclinix, Inc., to recruit volunteers for their Phase III clinical trial of a Travelers' Diarrhea (TD) vaccine system. The TD vaccine is in the form of a skin patch -- a novel method for delivering a vaccine that is especially compelling because it is needle-free.

This year, approximately 55 million international travelers will visit countries where bacteria that cause TD are endemic, particularly Africa, Asia and Latin America, and nearly 20 million of those travelers develop TD. The effects extend beyond the acute symptoms of the disease; between 10 and 30 percent of those who develop TD will develop the chronic symptoms of irritable bowel syndrome. If approved, this would be the first vaccine for TD available in the US.

Inclinix, a Wilmington, NC-based clinical trial enrollment solutions provider, will utilize its innovative recruitment tactics to drive the enrollment of 1200 volunteers in the US and 600 in Western Europe beginning in April 2009.

"We are pleased that Intercell AG has chosen Inclinix as their partner for the TD study," says J. Tobin Geatz, President and CEO, Inclinix. "We look forward to the opportunity to contribute to the development of this novel drug that has potential to make a truly global impact on the medical community."

The recruitment strategy for this study, appropriately named the "Trek Study" (, centers on reaching out to specific groups most likely to respond to free travel to Mexico or Guatemala while focusing on the social and altruistic impacts of clinical trial participation.

In order to build awareness of the Trek Study, Inclinix has developed partnerships with major travel and tourism websites. In addition, Recruitment Monitors -- in-field enrollment experts -- will execute events in communities near investigators' sites. "Traditional media combined with a strong relevant social and mobile networking presence is a fundamental element of this enrollment campaign," explains Diane Montross, Director of Patient Recruitment for Inclinix. "We are thrilled to be using such innovative solutions to get the message out. Social communication avenues allow Inclinix to reach a unique audience. We are defining the next patient recruitment landscape."

Trek Study coordinators will be in contact with volunteers through a variety of online and print communications, building excitement and providing helpful study and travel information. The Trek Study website, allows interested participants to register to receive continuously updated information on topics such as travel destinations, group travel and study compensation. Volunteers will receive compensation of up to $1500 for participation, along with pre-paid mobile phones and welcome kits with useful travel tools. In a groundbreaking effort to encourage group travel, the Trek Study also features a program that provides referral compensation to refer friends.

About the Trek Study

Based on compelling Phase II safety and efficacy data, this pivotal Phase III trial will follow approximately 1800 healthy volunteers age 18+ to Mexico and Guatemala, beginning in April 2009. Volunteers will receive two doses of the TD vaccine or a placebo, two weeks apart, with the last dose at least seven days prior to travel. Volunteers will then be surveyed via diary and visits for 17 days. The purpose of this trial is to evaluate the efficacy of the TD vaccine system.

The successful Phase II study followed 170 healthy travelers aged 18-64 to Mexico and Guatemala. The study found that of the 59 individuals who received the vaccine, only three suffered from moderate or severe diarrhea, while 23 of the 111 receiving a placebo suffered from moderate or severe diarrhea, a 75 percent reduction (p=0.007). No vaccine-related serious adverse events were reported.

About Intercell AG

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants, which are derived from its proprietary technology platforms, and has in-house GMP manufacturing capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kirin, and the Statens Serum Institut.

Intercell is listed on the Prime Market of the Vienna Stock Exchange under the symbol "ICLL"

    ISIN: AT0000612601
    For more information please visit:

About Inclinix

Inclinix, Inc. specializes in customized Phase I-IV clinical trial enrollment solutions that deliver productive investigator sites and qualified patients resulting in successfully completed clinical trials for the pharmaceutical, biotech and medical device industry. Clients benefit from ten years of experience in multiple therapeutic areas, as well as leading edge technologies that meet the challenge of clinical development from feasibility through compliance.

For more information please visit:

SOURCE Inclinix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
2. Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection
3. Favourable Six Months Follow-Up Results From Intercells Phase II Therapeutic Hepatitis C Program
4. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
10. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
11. UNICEF Partners With Causes on Facebook to Launch Charity Gift Feature
Post Your Comments:
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):